Radionuclide therapy of malignant bone lesions

Letter to the Editor
  • 467 Downloads

References

  1. 1.
    Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016;43:1896–909.CrossRefPubMedGoogle Scholar
  2. 2.
    Zlotta AR, Schulman CC. Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet. 2001;357:326–7. Commentary.CrossRefPubMedGoogle Scholar
  3. 3.
    Deguchi T, Yang M, Ehara H, Ito S, Nishino Y, Takahashi Y, et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer. 1997;75:634–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    US Food and Drug Administration. FDA Public Workshop on Clinical Trial Endpoints in Prostate Cancer, 21–22 June 2004. Silver Spring, MD: US Food and Drug Administration. http://www.fda.gov/ cancer drug approval endpoints
  5. 5.
    Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;9:1084–6.CrossRefGoogle Scholar
  7. 7.
    Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52:1721–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Kuroda I. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med. 2014;28:11–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J Nucl Med. 1993;34:1839–44.PubMedGoogle Scholar
  11. 11.
    Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1023–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(1):171–8.CrossRefGoogle Scholar
  13. 13.
    Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79–86.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Institut of Radiologie, Strahlentherapie und NuklearmedizinKasselGermany
  2. 2.Klinik und Poliklinik für NuklearmedizinUniversität BonnBonnGermany

Personalised recommendations